文献速递神经核医学肿瘤 PET/CT

脑渗透性PARP PET显像探针在大鼠胶质母细胞瘤及非人灵长类中的临床前评价

Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-02-28

本研究合成脑渗透性PARP PET示踪剂[11C]PyBic,在大鼠RG2胶质母细胞瘤模型和健康非人灵长类中进行临床前评价。结果显示[11C]PyBic放化纯度和化学纯度均大于97%,摩尔活度为148±85 MBq/nmol(n=6),肿瘤中74%的示踪剂结合可被预注射维利帕尼(静脉,5 mg/kg)阻断;猴脑PET显示高特异性摄取(BPND>3)和低非特异性摄取(VND<3 mL/cm3)。结论认为[11C]PyBic是首个在大鼠胶质母细胞瘤模型和健康非人灵长类中验证的脑渗透性PARP PET示踪剂。

要点

  • [11C]PyBic一步合成,放化纯度和化学纯度均大于97%,摩尔活度为148±85 MBq/nmol(n=6)。
  • RG2肿瘤中74%的示踪剂结合可被预注射维利帕尼(静脉,5 mg/kg)阻断,显示PARP特异性结合。
  • 猴脑PET显示高特异性摄取(BPND>3)和低非特异性摄取(VND<3 mL/cm3),证实脑渗透性。

核心结论

  • [11C]PyBic是首个在大鼠胶质母细胞瘤模型和健康非人灵长类中验证的脑渗透性PARP PET示踪剂。

研究设计与样本

  • 合成脑渗透性PARP PET示踪剂[11C]PyBic,在大鼠RG2胶质母细胞瘤模型和健康非人灵长类中进行临床前评价。
  • 在大鼠RG2肿瘤模型中进行动态PET扫描,以对侧非肿瘤脑区为参考区域,采用简化参考区域法2(SRTM2)计算分布容积比(DVR)。
  • 进行生物分布研究、蛋白质印迹和免疫染色研究以验证体内PET定量结果。
  • 在非人灵长类FOCUS220扫描仪上表征[11C]PyBic的脑动力学和结合特异性,计算选定脑区的分布容积(VT)、非可置换分布容积(VND)和非可置换结合电位(BPND)。

主要发现

  • [11C]PyBic一步合成,放化纯度和化学纯度均大于97%,摩尔活度为148±85 MBq/nmol(n=6)。
  • [11C]PyBic在RG2肿瘤中显示PARP特异性结合,肿瘤中74%的示踪剂结合被预注射维利帕尼(静脉,5 mg/kg)阻断。
  • 体内PET显像结果与离体生物分布、PARP1免疫组化和免疫印迹数据一致。
  • 猴脑定量PET显示高特异性摄取(BPND>3)和低非特异性摄取(VND<3 mL/cm3),证实[11C]PyBic的脑渗透性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Currently, there are multiple active clinical trials involving poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of glioblastoma. The noninvasive quantification of baseline PARP expression using positron emission tomography (PET) may provide prognostic information and lead to more precise treatment. Due to the lack of brain-penetrant PARP imaging agents, the reliable and accurate in vivo quantification of PARP in the brain remains elusive. Herein, we report the synthesis of a brain-penetrant PARP PET tracer, (R)-2-(2-methyl-1-(methyl-11C)pyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide ([11C]PyBic), and its preclinical evaluations in a syngeneic RG2 rat glioblastoma model and healthy nonhuman primates. METHODS: We synthesized [11C]PyBic using veliparib as the labeling precursor, performed dynamic PET scans on RG2 tumor-bearing rats and calculated the distribution volume ratio (DVR) using simplified reference region method 2 (SRTM2) with the contralateral nontumor brain region as the reference region. We performed biodistribution studies, western blot, and immunostaining studies to validate the in vivo PET quantification results. We characterized the brain kinetics and binding specificity of [11C]PyBic in nonhuman primates on FOCUS220 scanner and calculated the volume of distribution (VT), nondisplaceable volume of distribution (VND), and nondisplaceable binding potential (BPND) in selected brain regions. RESULTS: [11C]PyBic was synthesized efficiently in one step, with greater than 97% radiochemical and chemical purity and molar activity of 148 ± 85 MBq/nmol (n = 6). [11C]PyBic demonstrated PARP-specific binding in RG2 tumors, with 74% of tracer binding in tumors blocked by preinjected veliparib (i.v., 5 mg/kg). The in vivo PET imaging results were corroborated by ex vivo biodistribution, PARP1 immunohistochemistry and immunoblotting data. Furthermore, brain penetration of [11C]PyBic was confirmed by quantitative monkey brain PET, which showed high specific uptake (BPND > 3) and low nonspecific uptake (VND < 3 mL/cm3) in the monkey brain. CONCLUSION: [11C]PyBic is the first brain-penetrant PARP PET tracer validated in a rat glioblastoma model and healthy nonhuman primates. The brain kinetics of [11C]PyBic are suitable for noninvasive quantification of available PARP binding in the brain, which posits [11C]PyBic to have broad applications in oncology and neuroimaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen B, Ojha DP, Toyonaga T, et al. Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates. Eur J Nucl Med Mol Imaging. 2023. PMID: 36849748. doi:10.1007/s00259-023-06162-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。